Selected article for: "dependent variable and ICU need"
Author: Sukkar, SG; Cogorno, L; Pisciotta, L; Pasta, A; Vena, A; Gradaschi, R; Dentone, C; Guiddo, E; Martino, E; Beltramini, S; Donini, L.M.; Carmisciano, L; Sormani, MP; Bassetti, M
Title: Clinical efficacy of eucaloric ketogenic nutrition in the Covid-19 cytokine storm (CSS): a retrospective analysis of mortality and Intensive Care Unit admission
  • Cord-id: yzllipq5
  • Document date: 2021_3_7
    • ID: yzllipq5
    Snippet: OBJECTIVE: : Primary objective is to explore the effect of eucaloric ketogenic diet (EKD) on mortality, admission to intensive care unit (ICU) and the need for non-invasive ventilation (NIV) in hospitalized patients affected by COVID-19 in comparison to eucaloric standard diet (ESD). Secondary objectives are: the verification of safety and feasibility of the diet and its impact on inflammatory parameters, in particular interleukin-6 (IL-6). RESULTS: : The preliminary multivariate analysis shows
    Document: OBJECTIVE: : Primary objective is to explore the effect of eucaloric ketogenic diet (EKD) on mortality, admission to intensive care unit (ICU) and the need for non-invasive ventilation (NIV) in hospitalized patients affected by COVID-19 in comparison to eucaloric standard diet (ESD). Secondary objectives are: the verification of safety and feasibility of the diet and its impact on inflammatory parameters, in particular interleukin-6 (IL-6). RESULTS: : The preliminary multivariate analysis shows a statistical significance in survival (P=0,046) and need for ICU (P=0,049) with EKD compared with ESD. Considering EKD start day as a "time-dependent" variable, however, the results maintain a positive trend towards the application of the diet and it is not possible to reject the null hypothesis (p <0.05). IL-6 concentrations between t 0 and t 7 (seven days after the beginning of the diet) in the ketogenic nutrition group shows a trend almost significant (P = 0.062). EKD was safe and no adverse events were observed. CONCLUSIONS: : These results show a possible therapeutic role of EKD in the clinical management of COVID-19. Currently, a prospective controlled randomized trial is running out in order to confirm these preliminary data.

    Search related documents:
    Co phrase search for related documents
    • acid receptor and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acid receptor and acute respiratory distress syndrome: 1, 2, 3
    • acid receptor and liver disease: 1, 2, 3, 4
    • acid receptor and m1 phenotype: 1
    • actual state and acute respiratory: 1, 2
    • acute phase and additional cost: 1
    • acute phase and liver disease: 1, 2, 3, 4, 5, 6
    • acute phase and m1 phenotype: 1
    • acute respiratory and additional cost: 1, 2, 3, 4, 5, 6, 7, 8
    • acute respiratory and adequate control: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and low admission: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and m1 phenotype: 1, 2, 3
    • acute respiratory distress syndrome and additional cost: 1, 2
    • acute respiratory distress syndrome and adequate control: 1, 2, 3
    • acute respiratory distress syndrome and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and low admission: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute respiratory distress syndrome and m1 phenotype: 1, 2
    • adequate control and liver disease: 1